Compare NXDT & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | VTYX |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 713.6M |
| IPO Year | N/A | 2021 |
| Metric | NXDT | VTYX |
|---|---|---|
| Price | $3.29 | $8.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.60 |
| AVG Volume (30 Days) | 133.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.89 | $0.78 |
| 52 Week High | $13.07 | $10.55 |
| Indicator | NXDT | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 47.12 |
| Support Level | $2.65 | $8.39 |
| Resistance Level | $3.70 | $9.13 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.08 | -0.25 |
| Stochastic Oscillator | 63.30 | 20.35 |
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.